Article
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
BMC cancer - 17 Apr 2023
Julian Cristina, Pal Navdeep, Gershon Anda, Evangelista Marie, Purkey Hans, Lambert Peter, Shi Zhen, Zhang Qing
Abstract excerpt
BACKGROUND: KRAS mutations occur frequently in advanced non-small cell lung cancer (aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11 or KEAP1 commonly co-occur with KRAS mutations in aNSCLC. Using real-world data, we assessed the effect of KRAS G12C mutation with or without STK11 and/or KEAP1 mutations on overall survival (OS) in patients with aNSCLC receiving cancer immunotherapy (CIT),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.